CClinicalTrials.gg
Status unknownNCT03829865Updated Apr 26, 2021

Chicago Classification Normative Metrics in a Healthy Russian Cohort According to High-resolution Esophageal Manometry

An observational study in Healthy, sponsored by Russian Academy of Medical Sciences. Status unknown at 3 sites in Russian Federation. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-26.

Sponsored by Russian Academy of Medical Sciences · Observational

The sponsor has not verified this record recently (last verified Apr 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 65 Years
Sex
All
01

Study summary

High resolution esophageal manometry normative values are still need to be studied in different populations and with the use of solid-state and water-perfused systems. There has been no study on the subject in healthy Russian population yet.

Read the detailed description

High-resolution esophageal manometry (HREM) is the current modality used to evaluate esophageal motility. There are 2 types of system: water-perfused system that is cheaper to maintain and a solid-state system that is considered to be more sensitive. According to the data obtained in the study of 400 patients and 75 controls by J Pandolfino et al it was proposed to use a common algorithm of HREM data interpretation and the normative values of the parameters used to interpret the color plots of HREM. This formed the basis for the first version of the currently used HREM reporting algorithm and classification of esophageal motility disorders called Chicago Classification (CC). To date, this classification has been updated several times by the International Working Group based on the recently published data. The Working group stated that the proposed normative values still need to be widely studied for each HREM system and in different populations. Some studies has been published recently on the normative values of HREM in different countries (predominantly in the US, in some European countries, Korea, India and China. But there has been no study on the subject in Russia still.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Russian Academy of Medical Sciences is the lead sponsor of 34 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study is aimed to evaluate high resolution esophageal motility parameters in subjects who have no signs of any esophageal disorders and are residents of Russia

Eligibility criteria

Inclusion Criteria (all points are necessary for inclusion):

  • Willingness to participate on the basis of signed informed consent form;
  • Patients of both sexes, aged 18 to 65 years inclusive;
  • Permanent residence in the Russian Federation;
  • Absence of esophageal diseases, confirmed by the results of clinical and instrumental examination
  • Ability to follow instructions during high-resolution esophageal manometry procedure

Exclusion Criteria (patient is not eligible when at least one exclusion criterion is met):

  • diseases of the esophagus (any condition on the basis of clinical and / or instrumental examination, including: complaints of heartburn, belching, difficulty to swallow solid and/or liquid food;
  • any surgical intervention on the gastrointestinal tract and / or chest organs in medical history;
  • solid organ transplantation in medical history with the exception of a corneal transplant and surgery to replace the lens of the eye;
  • any oncology of any localization except for skin cancer in situ in the medical history;
  • any decompensated diseases of any organs and systems, which, in the opinion of the researcher, makes it impossible to carry out the procedure of esophageal manometry of high resolution or if the procedure may cause the risk of deterioration of the patient's condition;
  • any condition, clinical and laboratory signs of alcohol abuse (abuse will be assessed in the case of male subjects consuming more than 30 g of pure alcohol per day and using more than 20 g of pure alcohol per day by female subjects;
  • any illegal drug use, current or past;
  • use of concomitant medications that can affect esophageal motility including, but not limited to: calcium channel blockers, metoclopramide, m-cholinolytics, domperidone, erythromycin, nitrates, tricyclic antidepressants, opiates, beta-blockers, beta-adrenomimetics, alcohol. The duration of the period of non-use of these drugs should provide sufficient time for the complete cessation of their pharmacological action, but not less than two half-life.
  • pregnant or breastfeeding women
  • any condition making impossible to perform high resolution esophageal manometry (previously known poor tolerability of the procedure; narrow nasal passages; significant curvature of the nasal septum etc).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Water-perfused HREM

    Healthy volunteers examined with water-perfused high resolution esophageal manometry

    Diagnostic Test: High resolution esophageal manometry

  • Solid-state HREM

    Healthy volunteers examined with high resolution esophageal manometry with solid-state catheter

    Diagnostic Test: High resolution esophageal manometry

Interventions

  • Diagnostic testHigh resolution esophageal manometry

    High resolution esophageal manometry will be performed to eligible subjects willing to participate in the study

06

What researchers measure

Primary outcomes

  1. Mean IRP

    Integrated Relaxation Pressure - mean of the 4 s of maximal deglutitive relaxation in the 10-s window beginning at upper esophageal sphincter relaxation

    Time frame: mean value of 10 swallows by 30 seconds (about 7 minutes per subject)

  2. Mean DCI

    distal contractile integral - Amplitude x duration x length (mmHg x s x cm) of the distal esophageal contraction exceeding 20 mmHg from the transition zone to the proximal margin of the LES

    Time frame: mean value of 10 swallows by 30 seconds (about 7 minutes per subject)

  3. Mean DL

    distal latency - Interval between UES relaxation and the contractile deceleration point

    Time frame: mean value of 10 swallows by 30 seconds (about 7 minutes per subject)

  4. Mean upper esophageal sphincter mean resting pressure

    mean pressure of the upper esophageal sphincter

    Time frame: mean value based on 30 seconds measurement of a subject

  5. Mean lower esophageal sphincter mean resting pressure

    mean pressure of the upper esophageal sphincter

    Time frame: mean value based on 30 seconds measurement of a subject

07

Study locations

3 of 3 sites recruiting
  • Gastroenterology and Hepatology, FRC Nutrition and Biotechnology
    Moscow, 115446, Russian Federation
    Recruiting
  • Moscow clinical hospital #31
    Moscow, 119415, Russian Federation
    Recruiting
  • Pavlov First Saint Petersburg State Medical University. Endoscopy Department
    Saint Petersburg, 197022, Russian Federation
    • Alexandr A Smirnov, MD, PhD · Contact · smirnov-1959@yandex.ru · +78005507225
    • Maya M Kiriltseva, MD, PhD · Contact · kiriltseva@mail.ru · +78005507225
    • Alexandr A Smirnov, MD, PhD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Depersonalized individual data may be shared upon the study completion.

Supporting information: Study protocol, Sap, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03829865
Lead sponsor
Russian Academy of Medical Sciences
Responsible party
Vasily Isakov (MD, PhD, Professor, AGAF, Russian Academy of Medical Sciences) — Principal investigator
First posted
Feb 4, 2019
Start date
Feb 4, 2019
Primary completion
Dec 31, 2022 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Apr 26, 2021

Study contacts

Sergey Morozov, MD, PhD
Contact
morosoffsv@mail.ru
+74996131091
Vasily Isakov, MD, PhD
study chair · Federal Research Center of Nutrition and Biotechnology
Sergey Morozov, MD, PhD
principal investigator · Federal Research Center of Nutrition and Biotechnology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion